Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, M4N 3M5, Canada.
Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.
Breast Cancer Res Treat. 2018 Jun;169(2):359-369. doi: 10.1007/s10549-018-4693-2. Epub 2018 Jan 31.
Better tools are needed to estimate local recurrence (LR) risk after breast-conserving surgery (BCS) for DCIS. The DCIS score (DS) was validated as a predictor of LR in E5194 and Ontario DCIS cohort (ODC) after BCS. We combined data from E5194 and ODC adjusting for clinicopathological factors to provide refined estimates of the 10-year risk of LR after treatment by BCS alone.
Data from E5194 and ODC were combined. Patients with positive margins or multifocality were excluded. Identical Cox regression models were fit for each study. Patient-specific meta-analysis was used to calculate precision-weighted estimates of 10-year LR risk by DS, age, tumor size and year of diagnosis.
The combined cohort includes 773 patients. The DS and age at diagnosis, tumor size and year of diagnosis provided independent prognostic information on the 10-year LR risk (p ≤ 0.009). Hazard ratios from E5194 and ODC cohorts were similar for the DS (2.48, 1.95 per 50 units), tumor size ≤ 1 versus > 1-2.5 cm (1.45, 1.47), age ≥ 50 versus < 50 year (0.61, 0.84) and year ≥ 2000 (0.67, 0.49). Utilization of DS combined with tumor size and age at diagnosis predicted more women with very low (≤ 8%) or higher (> 15%) 10-year LR risk after BCS alone compared to utilization of DS alone or clinicopathological factors alone.
The combined analysis provides refined estimates of 10-year LR risk after BCS for DCIS. Adding information on tumor size and age at diagnosis to the DS adjusting for year of diagnosis provides improved LR risk estimates to guide treatment decision making.
需要更好的工具来估计保乳手术后(BCS)乳腺导管原位癌(DCIS)的局部复发(LR)风险。DCIS 评分(DS)在 E5194 和安大略 DCIS 队列(ODC)的 BCS 后被验证为 LR 的预测因子。我们结合了 E5194 和 ODC 的数据,并对临床病理因素进行了调整,以提供单独接受 BCS 治疗后 10 年 LR 风险的更精确估计。
合并 E5194 和 ODC 的数据。排除切缘阳性或多灶性患者。对每个研究都拟合了相同的 Cox 回归模型。采用患者特异性荟萃分析,根据 DS、年龄、肿瘤大小和诊断年份计算 10 年 LR 风险的精确权重估计值。
联合队列包括 773 名患者。DS 以及诊断时的年龄、肿瘤大小和诊断年份为 10 年 LR 风险提供了独立的预后信息(p≤0.009)。来自 E5194 和 ODC 队列的风险比对于 DS(每增加 50 个单位分别为 2.48 和 1.95)、肿瘤大小≤1cm 与>1-2.5cm(1.45 和 1.47)、年龄≥50 岁与<50 岁(0.61 和 0.84)以及年≥2000 年(0.67 和 0.49),均相似。与单独使用 DS 或单独使用临床病理因素相比,DS 联合肿瘤大小和诊断时的年龄可以预测更多的女性,其 10 年 LR 风险较低(≤8%)或较高(>15%)。
联合分析为 DCIS 接受 BCS 后的 10 年 LR 风险提供了更精确的估计。在调整诊断年份的 DS 中加入肿瘤大小和诊断时的年龄信息,可以提供改进的 LR 风险估计值,以指导治疗决策。